For research use only. Not for therapeutic Use.
Exatecan (CAT: I002235), also known as DX-8951f or SN-38b, is a synthetic topoisomerase I inhibitor. It is derived from the active metabolite of irinotecan, SN-38. Exatecan inhibits the action of the topoisomerase I enzyme, preventing the resealing of DNA strands during replication and transcription processes. This leads to the accumulation of DNA strand breaks and ultimately causes cell death. Exatecan has demonstrated potent anticancer activity, particularly against a variety of solid tumors. It has shown efficacy in clinical trials for the treatment of ovarian, lung, colorectal, and breast cancers. Exatecan represents a valuable option in cancer therapy, offering a targeted approach to inhibit tumor cell growth and proliferation.
| Catalog Number | I002235 |
| CAS Number | 171335-80-1 |
| Molecular Formula | C24H22FN3O4 |
| Purity | ≥95% |
| Target | topoisomerase I |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20C powder |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Exatecan is a DNA topoisomerase I inhibitor developed by Daiichi Sankyo Company. It has been granted for the new molecular entity. </span></span></span> |
| IUPAC Name | (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione |
| InChI | InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1 |
| InChIKey | ZVYVPGLRVWUPMP-FYSMJZIKSA-N |
| SMILES | O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O |
| Reference | 1:Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Chen X, Shi JG, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, Punwani NG, Williams WV, Yeleswaram S.Clin Pharmacol Drug Dev. 2014 Jan;3(1):34-42. doi: 10.1002/cpdd.77. Epub 2013 Oct 19. PMID: 27128228<br /> |
